WINTON GROUP Ltd Takes $6.04 Million Position in Illumina, Inc. $ILMN

Key Points

• WINTON GROUP Ltd acquired 34,357 Illumina shares worth approximately $6.04 million in the second quarter, while institutional investors collectively own 89.42% of the company.
• Analyst sentiment is mixed: Illumina has a consensus rating of “Hold” and an average price target of $199.12, despite several firms raising targets and maintaining “Buy” or “Outperform” ratings.
• Illumina exceeded quarterly expectations with $1.31 in EPS and $1.16 billion in revenue, up 9.4% year over year; however, insiders sold more than 2 million shares worth approximately $436.6 million over the past 90 days.

WINTON GROUP Ltd acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 34,357 shares of the life sciences company's stock, valued at approximately $6,041,000.

Several other hedge funds also recently made changes to their positions in the business. NewEdge Advisors LLC increased its stake in Illumina by 8.6% in the 2nd quarter. NewEdge Advisors LLC now owns 4,740 shares of the life sciences company's stock worth $833,000 after purchasing an additional 377 shares in the last quarter. IFP Advisors Inc lifted its stake in Illumina by 43.7% during the second quarter. IFP Advisors Inc now owns 1,930 shares of the life sciences company's stock valued at $339,000 after buying an additional 587 shares in the last quarter. Arizona State Retirement System lifted its stake in Illumina by 2.9% during the second quarter. Arizona State Retirement System now owns 42,742 shares of the life sciences company's stock valued at $7,515,000 after buying an additional 1,222 shares in the last quarter. West Family Investments Inc. acquired a new position in shares of Illumina in the second quarter worth about $219,000. Finally, Waverly Advisors LLC increased its position in shares of Illumina by 18.5% in the second quarter. Waverly Advisors LLC now owns 5,527 shares of the life sciences company's stock worth $972,000 after acquiring an additional 864 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Zacks Research downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 1st. Guggenheim boosted their target price on shares of Illumina from $200.00 to $226.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Sanford C. Bernstein reissued a "market perform" rating and set a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Argus increased their target price on Illumina from $180.00 to $235.00 and gave the company a "buy" rating in a report on Thursday, September 3rd. Finally, Daiwa Securities Group raised Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Illumina currently has a consensus rating of "Hold" and a consensus price target of $199.12.

Insider Buying and Selling at Illumina

In other news, Director Keith Meister sold 457,858 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares of the company's stock, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 2,062,465 shares of company stock worth $436,589,802. 2.90% of the stock is currently owned by insiders.

Illumina Price Performance

NASDAQ ILMN opened at $201.27 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $30.39 billion, a PE ratio of 37.55, a price-to-earnings-growth ratio of 2.90 and a beta of 1.46. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $231.81. The company has a 50 day moving average price of $200.54 and a two-hundred day moving average price of $161.87.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm's revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company's sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.